Bessemer Group
VRDN icon

Bessemer Group’s Viridian Therapeutics VRDN Stock Holding History

Bessemer Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41K Sell
2,085
-41
-2% -$1.22K ﹤0.01% 1731
2025
Q4 		$66K Buy
2,126
+41
+2% +$1.13K ﹤0.01% 1573
2025
Q3 		$45K Buy
2,085
+1,886
+948% +$34K ﹤0.01% 1462
2025
Q2 		$3K Buy
199
+165
+485% +$2.24K ﹤0.01% 2161
2025
Q1 		$0 Sell
34
-51
-60% -$869 ﹤0.01% 2739
2024
Q4 		$2K Hold
85
– – ﹤0.01% 2281
2024
Q3 		$2K Buy
+85
New +$1.39K ﹤0.01% 2290

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bessemer Group's VRDN Position: Q1 2026 in Review

Bessemer Group reduced its Viridian Therapeutics (VRDN) stake by 1.9% in Q1 2026, selling an estimated $1.22K and leaving 2,085 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #1731.

Bessemer Group first reported a position in VRDN in Q3 2024 and has held it in 7 quarters since. The position peaked at $66K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Bessemer Group held 2,085 shares of Viridian Therapeutics worth $41K as of Q1 2026.
  • Bessemer Group sold 41 Viridian Therapeutics shares in Q1 2026, an estimated $1.22K.
  • Viridian Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1731 holding.
  • Bessemer Group first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Bessemer Group's Viridian Therapeutics position peaked at $66K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.